focus -WSS

focus

author：Wikipedia 2025-09-29 21:23:01 - browse：32

Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022 — Photo illustration: STAT; Photo: Adobe

Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit that alleges she threatened to undermine a junior faculty member’s career, made defamatory comments about the younger scientist, and attempted to take credit for work that she didn’t do.

In legal filings submitted to the Harris County District Court, Sharma said that she made substantial contributions to an immunotherapy project that were ignored, and that a third-party assessment commissioned by MD Anderson Cancer Center concluded Sharma should be given credit for her role. Sharma had previously issued a general denial of the allegations against her and claimed immunity from the suit as a government employee. As part of the University of Texas, MD Anderson is a state institution.

The filing, which was submitted by Texas Attorney General Ken Paxton and lawyers in his office, also argued that the junior researcher’s lawsuit should be made against MD Anderson, not Sharma, and asked the court to dismiss the suit if it is not amended within 30 days. “Dr. Sharma is not a proper party to this lawsuit; only MDACC is,” the filing states. “This lawsuit is about proper accreditation in scientific literature for research performed at MDACC by MDACC faculty.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readers discuss the intersection of pregnancy and addiction

focus

leisure time

WSS

Curing rare childhood diseases will falter unless Congress steps up

Cardiologists urge adding sexual orientation, gender identity to health records

Study: Why relieving medical debt did not improve financial outcomes

New report analyzes digital physical therapy solutions' effectiveness

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Update the Apgar Score to remove skin color

focus

focus

hotspot

Peter Hotez and the public health issue of online harassment

STAT Virtual Event: ASCO Recap, Live!

The cancer drug shortage isn’t new — and neither are the solutions

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Virginia high school admissions case could be legal follow

FDA sets aggressive timeline for overhauling inspection procedures

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The inclusion problem at the heart of rehabilitation research

Hepatitis C has a cure — but many Americans still lack access to it

FDA endorses new sterilization method for medical devices

explore

Flu vaccine reformulation won't be easy, manufacturers warn

Dog Aging Project founders on what lies ahead after losing funding

Dana Farber says 6 studies to be retracted and 31 corrected

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Cardiologists urge adding sexual orientation, gender identity to health records

Head of FDA's diagnostics center, who led through Covid, retires

hotspot

focus

leisure time

focus